Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Published byBertalan Mezei Modified over 5 years ago

Similar presentations

Presentation on theme: "Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment."— Presentation transcript:

1 Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment strategies (p<0.001). Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment strategies (p<0.001). CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention. Per Mølstad et al. Open Heart 2016;3:e000489 ©2016 by British Cardiovascular Society

Download ppt "Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment."

Similar presentations

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349. ?

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.

Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):549-556.

Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Peter K. Smith, MD, Robert M. Califf, MD, Robert H
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
Successful CTO PCI Associated with Lower Mortality Risk

Successful CTO PCI Associated with Lower Mortality Risk
Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Mean eGFR among survivors after CABG surgery vs all-cause deaths

Mean eGFR among survivors after CABG surgery vs all-cause deaths
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 

Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy  Eric J. Velazquez, MD,

Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy  Eric J. Velazquez, MD,
Defining operative mortality: Impact on outcome reporting

Defining operative mortality: Impact on outcome reporting
Why surgery won the SYNTAX trial and why it matters

Why surgery won the SYNTAX trial and why it matters
Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS 

Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS 

Similar presentations

Ads by Google